Kiniksa Pharmaceuticals Showcases Growth in Recurrent Pericarditis Market and Advances Cardiovascular Drug Pipeline

Reuters2025-10-28

Kiniksa Pharmaceuticals Showcases Growth in Recurrent Pericarditis Market and Advances Cardiovascular Drug Pipeline

Kiniksa Pharmaceuticals International plc has highlighted ongoing progress in its cardiovascular portfolio, with a particular focus on recurrent pericarditis. The company reported more than $1 billion in revenue since the launch of ARCALYST®, which is approved for the treatment and reduction in risk of recurrence of recurrent pericarditis. ARCALYST® revenue for 2025 is projected between $670 million and $675 million, with continued growth potential indicated by approximately 15% market penetration among patients experiencing multiple recurrences. Kiniksa also announced the advancement of its clinical pipeline, including the initiation of a Phase 2/3 trial for KPL-387 in recurrent pericarditis, with Phase 2 dose-focusing data expected in the second half of 2026. The company maintains a strong financial position, reporting cash reserves of approximately $352 million as of the third quarter of 2025. You can access the full presentation through the link below.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Kiniksa Pharmaceuticals International plc published the original content used to generate this news brief on October 28, 2025, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2578409954?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-10-28 20:47","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2578409954","market":"nz","top_or_hot":-1,"title":"Kiniksa Pharmaceuticals Showcases Growth in Recurrent Pericarditis Market and Advances Cardiovascular Drug Pipeline","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Kiniksa Pharmaceuticals Showcases Growth in Recurrent Pericarditis Market and Advances Cardiovascular Drug Pipeline\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Kiniksa Pharmaceuticals International plc has highlighted ongoing progress in its cardiovascular portfolio, with a particular focus on recurrent pericarditis. The company reported more than $1 billion in revenue since the launch of ARCALYST®, which is approved for the treatment and reduction in risk of recurrence of recurrent pericarditis. ARCALYST® revenue for 2025 is projected between $670 million and $675 million, with continued growth potential indicated by approximately 15% market penetration among patients experiencing multiple recurrences. Kiniksa also announced the advancement of its clinical pipeline, including the initiation of a Phase 2/3 trial for KPL-387 in recurrent pericarditis, with Phase 2 dose-focusing data expected in the second half of 2026. The company maintains a strong financial position, reporting cash reserves of approximately $352 million as of the third quarter of 2025. You can access the full presentation through the link below.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Kiniksa Pharmaceuticals International plc published the original content used to generate this news brief on October 28, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Kiniksa Pharmaceuticals Showcases Growth in Recurrent Pericarditis Market and Advances Cardiovascular Drug Pipeline</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nKiniksa Pharmaceuticals Showcases Growth in Recurrent Pericarditis Market and Advances Cardiovascular Drug Pipeline\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-10-28 20:47</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Kiniksa Pharmaceuticals Showcases Growth in Recurrent Pericarditis Market and Advances Cardiovascular Drug Pipeline\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Kiniksa Pharmaceuticals International plc has highlighted ongoing progress in its cardiovascular portfolio, with a particular focus on recurrent pericarditis. The company reported more than $1 billion in revenue since the launch of ARCALYST®, which is approved for the treatment and reduction in risk of recurrence of recurrent pericarditis. ARCALYST® revenue for 2025 is projected between $670 million and $675 million, with continued growth potential indicated by approximately 15% market penetration among patients experiencing multiple recurrences. Kiniksa also announced the advancement of its clinical pipeline, including the initiation of a Phase 2/3 trial for KPL-387 in recurrent pericarditis, with Phase 2 dose-focusing data expected in the second half of 2026. The company maintains a strong financial position, reporting cash reserves of approximately $352 million as of the third quarter of 2025. You can access the full presentation through the link below.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Kiniksa Pharmaceuticals International plc published the original content used to generate this news brief on October 28, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"KNSA","symbol_name":"Kiniksa Pharmaceuticals Ltd.","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251028:nNDL65FFD4:1","article_id":"2578409954","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2578409954","pubTimestamp":1761655670,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Kiniksa Pharmaceuticals International plc has highlighted ongoing progress in its cardiovascular portfolio, with a particular focus on recurrent pericarditis. The company reported more than $1 billion in revenue since the launch of ARCALYST, which is approved for the treatment and reduction in risk of recurrence of recurrent pericarditis. ARCALYST revenue for 2025 is projected between $670 million and $675 million, with continued growth potential indicated by approximately 15% market penetration among patients experiencing multiple recurrences. Kiniksa also announced the advancement of its clinical pipeline, including the initiation of a Phase 2/3 trial for KPL-387 in recurrent pericarditis, with Phase 2 dose-focusing data expected in the second half of 2026. The company maintains a strong financial position, reporting cash reserves of approximately $352 million as of the third quarter of 2025. You can access the full presentation through the link below.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"KNSA":"Kiniksa Pharmaceuticals Ltd.","BK4505":"高瓴资本持仓","BK4139":"生物科技"},"translate_title":"Kiniksa Pharmaceuticals展示了复发性心包炎市场的增长并推进了心血管药物管道","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"KNSA":0.9},"content_text":"Kiniksa Pharmaceuticals Showcases Growth in Recurrent Pericarditis Market and Advances Cardiovascular Drug Pipeline\n    \n\n        Kiniksa Pharmaceuticals International plc has highlighted ongoing progress in its cardiovascular portfolio, with a particular focus on recurrent pericarditis. The company reported more than $1 billion in revenue since the launch of ARCALYST®, which is approved for the treatment and reduction in risk of recurrence of recurrent pericarditis. ARCALYST® revenue for 2025 is projected between $670 million and $675 million, with continued growth potential indicated by approximately 15% market penetration among patients experiencing multiple recurrences. Kiniksa also announced the advancement of its clinical pipeline, including the initiation of a Phase 2/3 trial for KPL-387 in recurrent pericarditis, with Phase 2 dose-focusing data expected in the second half of 2026. The company maintains a strong financial position, reporting cash reserves of approximately $352 million as of the third quarter of 2025. You can access the full presentation through the link below.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Kiniksa Pharmaceuticals International plc published the original content used to generate this news brief on October 28, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.13","shortVersion":"4.35.13","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2578409954","isCrawlerRequest":true}